First, the Hims advertisement violates your Guidelines for Health Related Product Advertising. According to the Guidelines, [p]rescription drug advertising must adequately reflect FDA guidelines for prescription drug commercials. Advertisements must also be accurate and not misleading, contain all material facts, communicate clearly that the product is available by prescription only, and instruct viewers to consult their physicians regarding the product. They must also disclose the most significant risks that appear in the labeling and contain a brief summary of all necessary information related to side effects and contraindications. Hims advertisement does not comply with any of these requirements, despite being specifically intended to market Hims prescription drug products including compounded, unapproved semaglutide
GLP-1 receptoragonisten Binnen onze praktijk zien we dat medicijnen als Saxenda en Ozempic steeds populairder worden voor gewichtsverlies bij mensen met overgewicht of obesitas
There were no significant changes in blood pressure or cholesterol levels.40 These results suggest that the heart benefits of GLP-1s may be due to their effects on weight and cardiac structure rather than traditional cardiovascular risk factors
If the pharmacist is hesitant to discuss these kinds of things, I would choose another pharmacy, Davis says
Animal models of fibrotic lung disease
An active-comparator new-user cohort design is less susceptible to healthy user bias and confounding by indication, because an active treatment with similar indication rather than non-users is the comparator [31, 32]
